Q-omics provides the consensus-scored SNORA80B profile across patient tissues and cancer cell-line models. SNORA80B expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SNORA80B is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, SNORA80B RNA expression shows 12,239 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, KICH, and LSCC as cancer lineages where SNORA80B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA80B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA80B survival associations across molecular data types. SNORA80B RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA80B RNA expression–survival associations across cancer types. High SNORA80B expression shows unfavorable associations in UCEC, COAD, MESO, UVM, KICH and LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SNORA80B RNA expression.
This table summarizes SNORA80B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA80B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA80B shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, STAD, ESCA and LUAD. The KICH box plot shows higher SNORA80B RNA expression in normal versus tumor tissue (log2 FC = −0.938, t-test p < 0.001).
This table shows molecular features associated with SNORA80B in patient tissues and cancer cell lines. In patient samples, SNORA80B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
